Amend pharmaceutical extensions of term

Policy ID: 
Policy development
Issue summary: 

As a result of Australia's Free Trade Agreement commitments, extensions of patent term (EoTs) are offered for up to five years for original pharmaceutical substances per se or pharmaceutical substances produced as a result of recombinant DNA technology.

The extension of term is intended to compensate for the lengthy regulatory delays in allowing original pharmaceuticals to get to market, and to encourage pharmaceutical R&D in Australia.

The Productivity Commission (PC) in its 2016 report into Australia's IP arrangements considered that the policy case for extensions of term is not sufficient, and has not been borne out by experience. The PC found that EoTs do not appear to encourage R&D, and have a limited effect on return on investment for bringing pharmaceuticals to Australia, while costing the government a considerable amount through the PBS.

The PC recommended that EoTs be substantially curtailed. The government noted this recommendation, and considered that further consultation and development of options was necessary.
Policy Development 04-Sept-2017
The Government is considering options. Consultation will occur as appropriate.
Productivity Commission

Policy feedback

Mandatory fields are marked with an asterisk *

More information
  • Files must be less than 10 MB.
  • Allowed file types: jpg jpeg png rtf pdf doc docx.
By clicking the submit button below, you consent to any personal information you provide through this form being handled in accordance with the Privacy Notice and the IP Australia Privacy Policy

Privacy Notice

The personal information you provide to the Policy Register (including through any submissions) is collected by IP Australia for the purposes of gaining stakeholder insights and feedback into various policy issues and feedback on the Policy Register trial. Your personal information is handled in accordance with our Privacy Policy and is protected by the Privacy Act 1988. Our Privacy Policy states how you may access and correct the personal information we hold; how we protect your personal information; how you may make a privacy complaint and how we will deal with your complaint; and the contact details for IP Australia’s Privacy Contact Officer. Please read our Privacy Policy for more information.

Any personal information you provide will be used for the purposes of administering the Policy Register and the Policy Register trial, responding to feedback, and contacting you in relation to any feedback. IP Australia may provide any personal information collected to IP Australia staff, the Department of Industry, Innovation and Science and the relevant Ministers’ offices. IP Australia will not disclose your personal information to any overseas recipients.

Whilst your personal information may be provided anonymously, IP Australia may not be able to contact you or respond to your feedback.

IP Australia will not otherwise use or disclose your personal information without your consent, unless authorised or required by or under law. By providing any personal information to the Policy Register (including through any submissions), you consent to your personal information being handled in accordance with this privacy notice and the IP Australia Privacy Policy.